Artificial intelligence research biotech Earendil Labs has penned an $885 million deal to use WuXi XDC’s linker-payload technology to create next-gen antibody-drug conjugates. | AI research biotech ...

Discover the transformation of antibody-drug conjugates (ADCs) from experimental to essential in cancer therapy with new ...

Antibody-drug conjugates (ADCs) have been in development for decades, but only about a dozen have received FDA approval. Clearly, ADCs still have some major challenges. Yet they have done little to ...

Antibody-drug conjugates (ADCs) represent the most successful class of active targeting drug-delivery systems, however, despite the increasing number of FDA approvals treatment-related adverse events ...

Antibody-drug conjugate (ADC) developers say innovations to linkers, the proteins bridging antibodies to their therapeutic payloads, are opening the door to more stable, selective ADCs with ...

Antibody-Drug Conjugates (ADCs) are a fast-growing modality in both cancerous and non-cancerous indications. To date 15 ADCs have been approved by the regulatory agencies as therapies for various ...

The ADC cytotoxic payloads and warheads market is thriving due to advancements in cancer therapies, involving chemical optimizations and linker technologies that boost therapeutic efficacy. Key ...

As the proportion of clinically site-specific ADCs increases, the abundance of novel conjugation technologies diversifies, and the linker chemistry toolkit is expanded, investments in linker and ...

DUBLIN--(BUSINESS WIRE)--The "Antibody-drug Conjugates: Technology Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. Antibody-drug conjugates (ADCs) are therapies that ...

WuXi XDC inks collaboration with Earendil Labs on WuXiTecan-2 payload-linker technology platform: Shanghai, China Monday, March 2, 2026, 17:00 Hrs [IST] WuXi XDC Cayman Inc. (WuXi ...

Antibody-drug conjugate (ADC) is a promising class of cancer treatments with accelerating U.S. Food and Drug Administration (FDA) approval and rapidly growing market size as discussed in previous ...

AMSTERDAM--(BUSINESS WIRE)--Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology that enables antibody-drug conjugates (ADCs) with best-in-class ...